CLINICAL TRIAL: EVALUATION OF CYCLOPHOSPHAMIDE WITH PEPTIDE VACCINES IN PARTICIP

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究旨在评估由I类和II类限制性肽组成的疫苗在晚期黑素瘤患者中的免疫原性。 本研究的目的是（a）测试包含黑素瘤衍生的II类MHC限制性辅助肽是否增强CD 8 + T细胞应答，（B）测试包含黑素瘤衍生的II类MHC限制性辅助肽是否影响CD 8 + T细胞应答的持续性，和（c）评估环磷酰胺对基于肽的疫苗的免疫原性的影响。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study was designed to assess the immunogenicity of a vaccine comprised of class I- and class II-restricted peptides in patients with advanced melanoma. The objectives of this study are to (a) test whether inclusion of melanoma-derived class II MHC-restricted helper peptides augments CD8+ T-cell responses, (b) test whether inclusion of melanoma-derived class II MHC-restricted helper peptides affects the persistence of CD8+ T-cell responses, and (c) evaluate the effects of cyclophosphamide on the immunogenicity of a peptide-based vaccine.